FourKites Signs on as Collaborator to Consortium of Supply Chain Leaders Working to Streamline Scheduling Technology Across the Logistics Industry
29.5.2024 10:00:00 EEST | Business Wire | Press release
Leading real-time supply chain visibility provider FourKites® today announced its role as a Collaborator in the Scheduling Standards Consortium (SSC) as the first real-time visibility platform participating. FourKites joins organisations involved with the SSC — including Arrive Logistics, BlueYonder, Coyote Logistics, DHL, e2open, Echo, J.B. Hunt Transport, Lineage, Mastery, One Network Enterprises, Oracle, Ryder, TI NTG, Uber Freight, Werner and Worldwide Express — which aims to foster greater efficiency within the supply chain technology landscape.
Freight scheduling has been a pervasive problem for the supply chain, compounded by the past decade’s tremendous growth and diversification in scheduling solutions. Shippers and carriers today are responsible for juggling dozens of methods of scheduling freight with shippers, each with their own interface and API, which creates friction and inefficiencies throughout the supply chain.
In response to this challenge, J.B. Hunt and Uber Freight joined forces in 2022 to establish the SSC, to create the first universal appointment scheduling standard in the form of an API. With many leading organisations now involved and driving the Standard forward, the SSC’s goal is to simplify the integration of systems across the fragmented ecosystem between shippers, carriers and intermediaries to create a more efficient appointment scheduling process. The SSC has endorsed a universal standard for the API, released October 2, 2023, which eliminates the need for multiple interfaces and allows carriers to interact through a single interface.
“Embracing a universal scheduling API unlocks seamless coordination across supply chains,” explains Viral Parekh, Head of Logistics Operations at The Kraft Heinz Company. “As more companies endorse this unified approach, we pave the way for unparalleled system efficiency, streamlining operations and driving transformative growth throughout the industry.”
FourKites is collaborating with the SSC because of its proven commitment to optimising ecosystem performance, carrier success and building a more user-friendly operating environment. In addition, FourKites’ robust customer base and recognised industry leadership enables it to play a role in developing the API and accelerating adoption across its customer and partner network. With over 100,000 appointments scheduled in the platform every month, Slot Manager is one of FourKites’ fastest-growing products, as it significantly eliminates the friction associated with manual time slot booking.
“We’re thrilled to participate in this consortium of industry heavy-hitters,” said Mathew Elenjickal, founder and CEO of FourKites. “A single API between our Slot Manager solution and our shippers’ carrier networks will create a frictionless operating environment for everyone involved, and will make FourKites customers Shippers of Choice, with lower cost to serve and a reliable, reputable integration.”
The SSC’s main objectives are to define the API standard for sharing scheduling information, eliminate manual processes by automating interactions where possible, implement standardised interfaces and integrations across core platforms, and advocate the standard across the industry.
About the Scheduling Standards Consortium (SSC)
Founded in 2022 by Convoy, J.B. Hunt and Uber Freight, the Scheduling Standards Consortium (SSC) was established to create freight appointment scheduling standards that provide consistent visibility into the supply chain. Together with shippers, carriers and intermediaries, the SSC aims to simplify the integration of systems across the fragmented ecosystem and generate efficiency across the freight industry. To learn more, visit www.FreightAPIs.org.
About FourKites
Leading global supply chain visibility platform FourKites® empowers business leaders with comprehensive visibility into transportation, yards, warehouses, stores and beyond. Tracking more than 3.2 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,500 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529642423/en/
Contact information
Media:
Scott Johnston
European PR Director, FourKites
scott.johnston@fourkites.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
